Expression And Clinical Significance Of BCL9 And β-catenin In Breast Cancer

Objective: To investigate the expression of B-cell lymphoma9(BCL9)and β-catenin in different breast tissues and their correlation with the clinicopathological features of breast cancer.Method: A total of 228 patient are involved in this study.Among these collected cases,there are 120 cases of invasive ductal carcinoma(IDC),38 cases of ductal carcinoma in situ with microinvasion(DCIS-MI),50 cases of ductal carcinoma in situ(DCIS)and 20 cases of normal tissues besides breast cancinoma.The Envision immunohischemical staining is used to test expression of BCL9 andβ-catenin in the mentioned tissues.Its expressions in different tissues and the relationship with clinicopathological features in IDC are analyzed.Statistical treatment via SPPSS17.0,enumeration data by Chi-square test,pairwise comparison by Fisher’s exact test and correlation analysis by Spearman correlation test are performed.Finally,value of P<0.05 denoted a statistically significant difference.Result:1.The expression of BCL9 in normal tissues,DCIS,DCIS-MI and IDC was 0,32%,44.7% and 53.3%,respectively(P<0.05).The expression of BCL9 in IDC is higher than that in DCIS(P<0.05);There’sno obvious difference between DCIS-MI and DCIS,DCIS-MI and IDC(P>0.05).2.The abnormal expression of β-catenin in normal tissues,DCIS,DCIS-MI and IDC is 20%,56%,60.5% and 71.7%,respectively(P<0.05).The abnormal expression of β-catenin in DCIS、DCIS-MI、IDC is higher than that in normal tissues(P<0.05).The abnormal expression ofβ-catenin in IDC is higher than that in DCIS(P<0.05).The abnormal expression of β-catenin in DCIS-MI is not obviously different from that in IDC and DCIS(P>0.05).3.BCL9 expression is associated with the size of tumor,ER,PR,the HER-2 expression and Ki-67,molecular typing(P<0.05).At the same time,it’s irrelevant to patient’s age,WHO classification,carcinoma cell embolus,lymph node metastasis,distant metastasis and pTNM stage(P>0.05).4.The abnormal expression of β-catenin is related to blood vessel invasion,ER and HER-2 expression,molecular typing(P<0.05).it is not connected with patient’s age,the tumor size,lymph node metastasis,distant metastasis,WHO classification,pTNM stage,PR and Ki-67(P>0.05).5.By Spearman correlation analysis,BCL9 positive expression in breast cancer shows a positive correlation with the abnormal expressionof β-catenin(r=0.612,P=0.000).Conclusion:1.The gradually increasing expression of BCL9 in normal tissues,DCIS,DCIS-MI and IDC can explain that BCL9 expression does correlate with the occurrence and progress of breast carcinoma.Expression of BCL9 in IDC is higher than that in DCIS,showing a possibility of BCL9 with the invasion of ductal carcinoma in situ.2.The progressive increase of abnormal expression of β-catenin in normal tissues,DCIS,DCIS-MI and IDC shows that abnormal expression of β-catenin may be linked with the occurrence and progress of breast neoplasm.Expression in IDC is higher than that in DCIS,giving a hint of a potential relationship between the abnormal expression of β-catenin and the invasion of ductal carcinoma in situ.3.The higher expression of BCL9 in IDC is related to breast T classification of breast,ER(-),PR(-),HER-2’s positive expression and Ki-67 high expression.The expression of BCL9 in Basal-like molecular typing,HER-2 overexpression and Luminal B is higher than those in Luminal A.4.The abnormal expression of β-catenin in IDC is higher in patients with blood vessel invasion,ER(-)and HER-2 positive expression.The abnormal expression of β-catenin in Basal-like molecular typing,HER-2overexpression and Luminal B is higher than that in Luminal A.5.BCL9 positive expression in breast cancer shows a positive correlation with the abnormal expression of β-catenin.